Making chemotherapy work better for colorectal cancer by targeting β‑TrCP regulators
Targeting ß-TrCP regulators to improve CRC response to chemotherapy
['FUNDING_R01'] · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · NIH-11284032
The team will try blocking proteins that boost a cancer-promoting regulator (β‑TrCP) to help chemotherapy work better for people with colorectal cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | PENNSYLVANIA STATE UNIV HERSHEY MED CTR (nih funded) |
| Locations | 1 site (HERSHEY, UNITED STATES) |
| Trial ID | NIH-11284032 on ClinicalTrials.gov |
What this research studies
This project studies two proteins, IGF2BP1 and PARP11, that help the β‑TrCP enzyme drive colorectal tumor growth and resistance to chemotherapy. Researchers will change these proteins in cancer cells and in immune cells around tumors to see how tumors grow, spread, and respond to the FOLFOX chemotherapy regimen. Most experiments will use lab-grown cells and animal models while measuring tumor size, metastasis, survival, and immune responses. The goal is to find ways to weaken tumors' defenses so standard chemotherapy helps patients more.
Who could benefit from this research
Good fit: People with colorectal cancer, especially those receiving or eligible for FOLFOX chemotherapy, would be the most relevant candidates for this research.
Not a fit: People with other types of cancer or colorectal tumors that do not rely on the β‑TrCP pathway are less likely to benefit from these findings.
Why it matters
Potential benefit: If successful, this work could make FOLFOX chemotherapy more effective and reduce tumor growth and spread in colorectal cancer patients.
How similar studies have performed: Previous lab studies and preliminary data link β‑TrCP, IGF2BP1, and PARP11 to chemotherapy resistance, but this specific targeting approach remains largely preclinical and unproven in patients.
Where this research is happening
HERSHEY, UNITED STATES
- PENNSYLVANIA STATE UNIV HERSHEY MED CTR — HERSHEY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SPIEGELMAN, VLADIMIR S. — PENNSYLVANIA STATE UNIV HERSHEY MED CTR
- Study coordinator: SPIEGELMAN, VLADIMIR S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.